Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icalcaprant in Major Depressive Disorder
NCT07276997Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icalcaprant in major depressive disorder (MDD), sponsored by AbbVie Inc.. Started Dec 2025; status: recruiting.
02
Drugs
icalcaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07276997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276997.